Author

Yan Sun

Observed names: Y Sun, Y. Sun, Y.C. Sun

Observed institutions: Shenyang Pharmaceutical University, Nanjing University of Chinese Medicine, Anhui Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Medical College of Wisconsin, Rabin Medical Center, Tianjin Medical University Cancer Institute and Hospital, AbbVie (United States), Bristol-Myers Squibb (United States), First Affiliated Hospital of Xi'an Jiaotong University, Cancer Hospital of Chinese Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Henan Medical College, Tianjin Medical University, Southern Medical University, Xi'an Jiaotong University

ORCID: 0000-0001-7856-7195

Observed ORCIDs: 0000-0001-7856-7195, 0000-0001-8916-9598

OpenAlex ID: A5018469890

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

2021 · Vinod A. Pullarkat, Norman J. Lacayo, et al. · Cancer Discovery · 302

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

2024 · Hartmut Döhner, Keith W. Pratz, et al. · Blood · 157

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

2022 · Daniel A. Pollyea, Keith W. Pratz, et al. · Clinical Cancer Research · 155

[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].

2005 · Jinwan Wang, Yan Sun, et al. · PubMed · 147

Patient subgroup identification for clinical drug development

2017 · Xin Huang, Yan Sun, et al. · Statistics in Medicine · 60

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

2022 · Andrew H. Wei, Panayiotis Panayiotidis, et al. · Blood · 40

6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

2021 · Andrew H. Wei, Panayiotis Panayiotidis, et al. · Blood Cancer Journal · 38

PDF

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

2019 · Simon Harrison, Michele Cavo, et al. · Blood · 37

[A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients].

2006 · Yan Sun, Hongsheng Lin, et al. · PubMed · 37

Deep Learning Based Multimodal Progression Modeling for Alzheimer’s Disease

2021 · Liuqing Yang, Xifeng Wang, et al. · Statistics in Biopharmaceutical Research · 28

Selective translation of nuclear mitochondrial respiratory proteins reprograms succinate metabolism in AML development and chemoresistance

2024 · Guoqiang Han, Manman Cui, et al. · Cell stem cell · 25

Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma

2020 · Hao Xie, Frederic J. Kaye, et al. · The Oncologist · 25

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

2021 · Jacqueline S. Garcia, Andrew H. Wei, et al. · Blood · 24

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents

2021 · Daniel A. Pollyea, Keith W. Pratz, et al. · Blood · 22

Effect of Dimethylsulfoxide and Hydroxyethyl Starch in the Preservation of Fractionated Human Marrow Cells

1994 · Kehuan Luo, Guanqing Wu, et al. · Cryobiology · 19

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

2019 · Brenda J Chyla, Jason Harb, et al. · Blood · 17

[Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].

2005 · Peng Yuan, Xiao-Ping Miao, et al. · PubMed · 15

[Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms].

2006 · Peng Yuan, Xiao-ping Miao, et al. · PubMed · 10

The Key Role of Tumor Budding in Predicting the Status of Lymph Node Involvement in Early Gastric Cancer Patients: A Clinical Multicenter Validation in China

2024 · Xiangyu Wang, Xiuding Yang, et al. · Annals of Surgical Oncology · 8

c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer.

2019 · Rebecca Suk Heist, Monica Motwani, et al. · Journal of Clinical Oncology · 7

Cytogenetic and Molecular Drivers of Outcome with Venetoclax-Based Combination Therapies in Treatment-Naïve Elderly Patients with Acute Myeloid Leukemia (AML)

2018 · Stephen A. Strickland, Brenda Chyla, et al. · Clinical Lymphoma Myeloma & Leukemia · 6

Targeting KRASG12C Mutation: Development of effective strategies to overcome drug resistance and limited efficacy

2025 · Rui Li, Xu Huang, et al. · European Journal of Medicinal Chemistry · 5

VPS35/Retromer-dependent MT1-MMP regulation confers melanoma metastasis

2025 · Qinggang Hao, Yan Bai, et al. · Science China Life Sciences · 5

BioPred: an R package for biomarkers analysis in precision medicine

2024 · Zihuan Liu, Yan Sun, et al. · Bioinformatics · 5

Predictive signature development based on maximizing the area between receiver operating characteristic curves

2022 · Xin Huang, Lu Tian, et al. · Statistics in Medicine · 5

PDF

Works count: 71

Citation count: 1,232

H-index: 16

I10-index: 18